Short Interest in Integra LifeSciences Holdings Co. (NASDAQ:IART) Decreases By 9.2%

Integra LifeSciences Holdings Co. (NASDAQ:IARTGet Free Report) saw a large decrease in short interest during the month of August. As of August 31st, there was short interest totalling 2,570,000 shares, a decrease of 9.2% from the August 15th total of 2,830,000 shares. Based on an average trading volume of 654,400 shares, the short-interest ratio is presently 3.9 days. Approximately 3.6% of the shares of the stock are sold short.

Wall Street Analyst Weigh In

A number of equities research analysts have recently issued reports on the company. assumed coverage on Integra LifeSciences in a research report on Thursday, August 17th. They set a “hold” rating on the stock. Piper Sandler lowered their price target on shares of Integra LifeSciences from $55.00 to $44.00 in a report on Monday, June 26th. Morgan Stanley downgraded Integra LifeSciences from an “equal weight” rating to an “underweight” rating and set a $44.00 target price on the stock. in a research note on Thursday, August 24th. Argus downgraded Integra LifeSciences from a “buy” rating to a “hold” rating in a report on Thursday, June 8th. Finally, JMP Securities cut their price target on shares of Integra LifeSciences from $65.00 to $60.00 and set an “outperform” rating on the stock in a report on Friday, July 28th. Three equities research analysts have rated the stock with a sell rating, three have given a hold rating and two have issued a buy rating to the company’s stock. Based on data from, the company presently has an average rating of “Hold” and an average price target of $47.29.

Read Our Latest Stock Report on IART

Integra LifeSciences Stock Performance

Shares of NASDAQ:IART traded up $0.01 during trading on Tuesday, hitting $39.27. 339,339 shares of the stock were exchanged, compared to its average volume of 617,874. Integra LifeSciences has a 1-year low of $37.36 and a 1-year high of $60.69. The company has a debt-to-equity ratio of 0.79, a quick ratio of 1.85 and a current ratio of 2.78. The company’s fifty day simple moving average is $42.89 and its 200-day simple moving average is $46.85. The company has a market capitalization of $3.20 billion, a price-to-earnings ratio of 25.01, a price-to-earnings-growth ratio of 1.60 and a beta of 1.20.

Integra LifeSciences (NASDAQ:IARTGet Free Report) last announced its earnings results on Wednesday, July 26th. The life sciences company reported $0.71 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.14. Integra LifeSciences had a return on equity of 15.60% and a net margin of 8.49%. The company had revenue of $381.30 million during the quarter, compared to analyst estimates of $388.79 million. During the same period last year, the company posted $0.82 earnings per share. The firm’s quarterly revenue was down 4.1% compared to the same quarter last year. Sell-side analysts expect that Integra LifeSciences will post 3.14 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. Itau Unibanco Holding S.A. raised its stake in Integra LifeSciences by 469.5% during the 2nd quarter. Itau Unibanco Holding S.A. now owns 746 shares of the life sciences company’s stock worth $31,000 after buying an additional 615 shares during the period. CWM LLC raised its position in shares of Integra LifeSciences by 107.0% during the second quarter. CWM LLC now owns 828 shares of the life sciences company’s stock worth $34,000 after purchasing an additional 428 shares during the period. Global Retirement Partners LLC lifted its holdings in shares of Integra LifeSciences by 3,103.7% during the 1st quarter. Global Retirement Partners LLC now owns 865 shares of the life sciences company’s stock valued at $44,000 after purchasing an additional 838 shares in the last quarter. Covestor Ltd increased its stake in Integra LifeSciences by 63.0% during the 1st quarter. Covestor Ltd now owns 1,558 shares of the life sciences company’s stock worth $100,000 after purchasing an additional 602 shares in the last quarter. Finally, Captrust Financial Advisors increased its position in shares of Integra LifeSciences by 95.0% during the first quarter. Captrust Financial Advisors now owns 2,003 shares of the life sciences company’s stock worth $129,000 after acquiring an additional 976 shares in the last quarter. Institutional investors and hedge funds own 84.13% of the company’s stock.

About Integra LifeSciences

(Get Free Report)

Integra LifeSciences Holdings Corporation manufactures and sells surgical instruments, neurosurgical products, and wound care products for use in neurosurgery, neurocritical care and otolaryngology. It operates in two segments, Codman Specialty Surgical and Tissue Technologies. The company offers neurosurgery and neuro critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and surgical headlamps and instrumentation, as well as after-market services.

Read More

Receive News & Ratings for Integra LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra LifeSciences and related companies with's FREE daily email newsletter.